Skip to main content

Table 1 Preoperative clinical characteristics for all patients and patients grouped according to diabetes status, alongside a normal weight reference population

From: Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study

 

All patientsa (n = 220)

NDM (n = 151)

DMH-NDM (n = 34)

DMH-DMH (n = 20)

ANOVA p-valueb

Reference (n = 235)

T-test p-valuec

mean (SD)

mean (SD)

mean (SD)

mean (SD)

mean (SD)

Age (years)

44.6 (9.5)

42.1 (9.0)

50.5 (8.1)*

51.5 (7.4)*

7 e−9

45.5 (8.9)*

2 e−4

Gender (female/male)

150/70

113/38

18/16

9/11

0.01

120/115

1 e−6

Height (cm)

171.8 (9.6)

171.0 (9.8)

174.5 (8.0)

171.2 (11.4)

0.167

171.0 (9.4)

0.996

Weight (kg)

125.2 (21.6)

126.3 (22.4)

126.4 (20.6)

117.6 (19.7)

0.244

79.2 (15.5)*

1 e−61

BMI (kg/m2)

42.3 (5.8)

43.1 (5.9)

41.4 (5.4)

40.0 (3.6)*

0.006

27.0 (4.5)*

1 e−81

Systolic blood pressure (mmHg)

128 (14.7)

126.8 (14.9)

131.2 (12.6)

128.2 (14.7)

0.285

132.1 (19.1)*

0.004

Diastolic blood pressure (mmHg)

82.2 (10.1)

82.0 (11.0)

81.4 (6.8)

82.4 (10.1)

0.93

82.3 (16.7)

0.831

HbA1c (mmol/mol)

39.0 (9.7)

34.5 (3.8)

48.8 (11.7)*

55.2 (10.0)*

4 e−12

40.7 (5.8)*

5 e−26

HbA1c (%)

5.7 (0.89)

5.3 (0.35)

6.6 (1.07)

6.9 (0.91)

ND

5.9 (0.53)

ND

Total cholesterol (mmol/L)

4.74 (1.04)

4.98 (0.96)

4.22 (1.11)*

4.24 (1.17)*

4 e−5

5.54 (1.07)*

5 e−7

HDL-Cholesterol (mmol/L)

1.15 (0.30)

1.19 (0.29)

1.06 0.36)

1.09 (0.35)

0.038

1.35 (0.32)*

2 e−6

LDL-Cholesterol (mmol/L)

2.88 (0.95)

3.12 (0.85)

2.36 (0.97)* (n = 32)

2.27 (1.13)* (n = 18)

1 e−6

3.69 0.97) (n = 67)*

2 e−5

VLDL-Cholesterol (mmol/L)

0.71 (0.32)

0.67 (0.30)

0.75 (0.30) (n = 32)

0.89 (0.47) (n = 18)

0.086

0.58 (0.25) (n = 67)*

0.033

Triglycerides (mmol/L)

1.67 (1.09)

1.50 (0.74)

2.11 (1.95)

2.13 (1.26)

0.038

1.28 (0.83)*

0.008

Statin treatment (+/−)

49/171

12/139

17/17*

13/7*

5 e−7

NA

 
  1. Data are reported as mean (SD). If the number of patients with available clinical data was less than 95% of the total of patients in the group, the actual number is specified. SD Standard deviation, BMI Body mass index, HbA1c Glycated hemogobin, HDL High-density lipoprotein, LDL Low-density lipoprotein, VLDL Very low-density lipoprotein, NDM Patients without diabetes mellitus (DM), DMH-NDM Patients with DM in remission after Roux-en-y gastric bypass surgery (RYGB), DMH-DMH Patients with DM not in remission after RYGB. Reference, a population of healthy individuals with normal weight. a All patients also include 15 patients who belong to other subgroups than the three showed in table; b p-value from One-way ANOVA comparing the three patient-subgroup means; c p-value from independent samples t-test comparing the reference group mean to the mean in the patient subgroup NDM. * indicates significant difference (p < 0,05) when compared to the NDM group. No significant differences were found between the two diabetes subgroups. The two diabetes subgroups were not compared to the reference group. Post hoc p-values from Tukey and Games-Howell are not shown in table. Data on statin treatment were not available (NA) for the reference population